Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
From the article
You might also wanna read
Experimental drug apitegromab aims to prevent muscle loss from weight-loss injections
Apitegromab, a new drug currently in clinical trials, is being developed to prevent muscle loss (often called 'Ozempic butt') caused by GLP-
bbc.co.uk·1mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·19d ago
Wegovy's Canadian Launch and AI's Role in Accelerating Weight Drug Discovery
The article discusses the shifting metabolic health landscape, highlighting obesity as a complex disease and the launch of Wegovy in Canada
startuphub.ai·8d ago
Two Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesity
Two observational studies found that GLP-1 receptor agonists (like Ozempic, Wegovy) are associated with reduced breast cancer incidence in w
mdsc.pe·13d ago
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl
medlink.com·7mo ago
AI Analysis of Reddit Posts Identifies Potential Side Effects of GLP-1 Weight Loss Drugs
Researchers at the University of Pennsylvania used AI to analyze over 410,000 Reddit posts spanning six years to identify potential side eff
sciencealert.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.